MAPLE GROVE, Minn., Nov. 7, 2016 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith) today announced that it has entered into an exclusive agreement with Bluepharma S.A. to develop and distribute a generic product in a market category with U.S. sales greater than $75 million (IMS Health, 12 months ending in July 2016). This new collaboration underscores Upsher-Smith's commitment to expanding its strategic relationships and growing its generic product portfolio.
Under the terms of the agreement, Bluepharma will develop, manufacture and supply the product. Upsher-Smith will submit the Abbreviated New Drug Application (ANDA), and has exclusive rights to market and distribute the product in the United States as a generic under the Upsher-Smith label. Financial terms have not been disclosed. "For years, Upsher-Smith has been a trusted partner in the U.S. generics marketplace," said Rusty Field, President, Upsher-Smith. "Upsher-Smith's consistent growth and success within this market can be attributed to our ability to build solid strategic relationships with leading pharmaceutical companies, like Bluepharma who share in our commitment to delivering quality, high-value generic products to patients." About Upsher-Smith Upsher-Smith Laboratories, Inc., founded in 1919, is a growing, fully integrated pharmaceutical company dedicated to its mission of delivering high-value, high-quality therapies and solutions which measurably improve individuals' lives. As a family-owned pharmaceutical company, we are able to adapt and thrive in a dynamic healthcare environment. Our world is constantly evolving, and we are continually adapting to the ever-changing needs of patients, physicians, pharmacists, and healthcare organizations. Where there is a need, we will work to deliver solutions that simplify access to treatment, deliver better health outcomes, and enhance life. For more information, visit www.upsher-smith.com. About BluepharmaBluepharma is a Portuguese pharmaceutical company, based in Coimbra that is dedicated to offering high-quality pharmaceutical products at competitive prices, while making use of novel technology platforms and innovative solutions. Bluepharma offers an integrated approach, with activities carried out in three distinct areas, including the production of pharmaceutical drugs; the research, development and registration of pharmaceutical drugs; and the marketing of generic pharmaceuticals. Since 2009, Bluepharma is FDA approved for the manufacturing of solid pharmaceutical forms, becoming one of the first Portuguese pharmaceutical companies to export to the US market. Bluepharma has more than 15 years of experience in developing and producing pharmaceutical products and is committed to maintaining the highest-quality standards. 111971.01